Carlos Rogerio Figueiredo

TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity (2024)

Genes and Immunity

Langguth Miriam, Maranou Eleftheria, Koskela Saara A., Elenius Oskar, Kallionpää Roosa E., Birkman Eva-Maria, Pulkkinen Otto I., Sundvall Maria, Salmi Marko, Figueiredo Carlos R.

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

From antimicrobial to anticancer: the pioneering works of Prof Luiz Rodolpho Travassos on bioactive peptides (2023)

Brazilian Journal of Microbiology

Koskela Saara A, Figueiredo Carlos R

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities (2023)

British Journal of Cancer

Wang Mona M, Coupland Sarah E, Aittokallio Tero, Figueiredo Carlos R

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities (2023)

Journal of Pathology

Matareed Maisoon, Maranou Eleftheria, Koskela Saara A, Mehmood Arfa, Kalirai Helen, Coupland Sarah E, Figueiredo Carlos R

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Editorial: Hallmark of cancer: tumor promoting inflammation (2023)

Frontiers in Oncology

Roncati Luca, Figueiredo Carlos R

(Kirjoitus tai data-artikkeli tieteellisessä aikakauslehdessä (B1))

Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas (2023)

Frontiers in Immunology

Wang Mona M, Koskela Saara A, Mehmood Arfa, Langguth Miriam, Maranou Eleftheria, Figueiredo Carlos R

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

The road leading up to a world without cancer (2022)

InFLAMES Flagship Blog

Figueiredo Rogerio

(Yleistajuinen artikkeli tai blogikirjoitus (E1))

Applying Single-Cell Technology in Uveal Melanomas: Current Trends and Perspectives for Improving Uveal Melanoma Metastasis Surveillance and Tumor Profiling (2021)

Frontiers in Molecular Biosciences

Wang Mona Meng, Chen Chuanfei F, Lynn Myoe Naing, Figueiredo Carlos Rogerio, Tan Wei Jian, Lim Tong Seng, Coupland Sarah E, Chan Anita Sook Yee

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Loss of BAP1 Expression Is Associated With an Immunosuppressive Microenvironment in Uveal Melanoma, With Implications for Immunotherapy Development. (2020)

Journal of Pathology

De Figueiredo, Rogerio

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

New tools to prevent cancer growth and spread: a 'Clever' approach (2020)

British Journal of Cancer

Maija Hollmén, Carlos R. Figueiredo, Sirpa Jalkanen

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Ota yhteyttä

Linkit

Julkaisut

Järjestä:

TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity (2024)

From antimicrobial to anticancer: the pioneering works of Prof Luiz Rodolpho Travassos on bioactive peptides (2023)

Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities (2023)

Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities (2023)

Editorial: Hallmark of cancer: tumor promoting inflammation (2023)

Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas (2023)

The road leading up to a world without cancer (2022)

Applying Single-Cell Technology in Uveal Melanomas: Current Trends and Perspectives for Improving Uveal Melanoma Metastasis Surveillance and Tumor Profiling (2021)

Loss of BAP1 Expression Is Associated With an Immunosuppressive Microenvironment in Uveal Melanoma, With Implications for Immunotherapy Development. (2020)

New tools to prevent cancer growth and spread: a 'Clever' approach (2020)